National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Partially Closed Meeting
Published Date: 2/2/2026
Notice
Summary
The National Institute of Arthritis and Musculoskeletal and Skin Diseases is holding a meeting on June 2, 2026, that’s partly open to the public and partly closed to protect private info about grant applications. Researchers and the public can join the open session online or in person, while the closed session will review important funding decisions. This meeting helps decide who gets money to study arthritis and related diseases, shaping future research and treatments.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Public Open Session and Videocast
You can attend the open part of the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council meeting on June 2, 2026, from 9:30 a.m. to 2:00 p.m. in person at NIH Building 31 (31 Center Drive, Bethesda, MD 20892) or watch the videocast at https://videocast.nih.gov/. Registration is not required for the open portion.
Closed Session to Review Grant Applications
On June 2, 2026, from 2:15 p.m. to 4:30 p.m., the council will meet in closed session to review and evaluate grant applications; discussions may disclose confidential trade secrets, patentable material, or personal information and will be closed to protect that information. This closed review is part of deciding who receives research funding for arthritis and related diseases.
On‑site Security and Visitor ID Procedures
If you come to the NIH campus for the meeting, NIH security procedures require visitors to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and state the purpose of their visit; all visitor vehicles will be inspected before being allowed on campus.
Reasonable Accommodations Available
If you need special assistance to attend the open session (for example, sign language interpretation), you should notify the Contact Person in advance so NIH can provide reasonable accommodations for the June 2, 2026 meeting.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20151, Notice of NIH Tribal Consultations and Listening Session
The NIH is inviting Tribal leaders and members to join two important meetings and a listening session during the National Congress of American Indians Annual Convention in October 2026. They’ll talk about new health research projects, renewing support for Tribal health centers, and shaping a new Tribal Data Sovereignty Policy. Tribes can also send their thoughts by November 20, 2026, helping shape future health programs and policies.
2026-19718, Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding two closed virtual meetings in October 2026 to review important grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists and research teams applying for grants should note these dates as they impact funding decisions but don’t involve public attendance.
2026-19804, Submission for OMB Review; 30-Day Comment Request; Generic Clearance for NIH Citizen Science and Crowdsourcing Projects (Office of the Director)
The NIH is asking for approval to keep collecting info from citizen science and crowdsourcing projects, making it easier to gather public input on health research. This affects anyone involved in these projects and invites comments by October 28, 2026. No new costs or big changes, just a smooth way to keep the data flowing for better science!
2026-19719, Center for Scientific Review; Amended Notice of Meeting
The NIH’s Center for Scientific Review is shortening a key meeting from two days to just one day on October 13, 2026, keeping the same 9 a.m. to 6 p.m. hours. This change affects members of the Surgical Sciences and Bioengineering review group and means less time in the room but no public access. No money changes or delays are expected—just a quicker, tighter meeting!
2026-19706, Draft NIH Policy on Sharing Summary Level Study Results With Clinical Research Participants
The NIH wants to make it easier for people who join clinical studies to get simple summaries of the study results. This new policy aims to boost trust and teamwork between researchers and participants, helping science move faster and better. They’re asking for your thoughts by October 26, 2026, so get ready to share your ideas!
2026-19431, Government-Owned Inventions; Availability for Licensing
The government is offering a new invention for licensing that makes stem cell transplants safer and less harsh, especially for leukemia patients and older folks. This tech uses a special protein to prepare patients for transplants without the tough side effects of chemo and radiation. Companies can start licensing this preclinical innovation now to help bring better treatments to market faster.
Previous / Next Documents
Previous: 2026-01942, Eunice Kennedy Shriver National Institute of Child Health and Human Development; Amended Notice of Meeting
Heads up! The Eunice Kennedy Shriver National Institute of Child Health and Human Development is extending its big May 2026 meeting from one day to two days. This change affects anyone interested in medical rehab research and means more time for important discussions, all happening in Bethesda and open to the public.
Next: 2026-01944, Importer of Controlled Substances Application: Sharp Clinical Services, LLC
Sharp Clinical Services, LLC wants to become an official importer of certain controlled substances, including some Schedule I drugs like Gamma Hydroxybutyric Acid and MDMA. This affects companies involved in drug manufacturing and regulation, who can comment or request a hearing by March 4, 2026. No fees or immediate changes yet, but this step could impact drug supply chains soon.